FDA
6th May 2014

FDA AdComm Roll Call – Changes to Two Committees

This month we saw changes to two Advisory Committees – the Anesthetic and Analgesic Drug Advisory Committee (AADP) and the Pulmonary-Allergy Drugs Advisory Committee (PADAC).

FDA AdComm Roll Call – Changes to Two Committees

This month we saw changes to two Advisory Committees – the Anesthetic and Analgesic Drug Advisory Committee (AADP) and the Pulmonary-Allergy Drugs Advisory Committee (PADAC).

The AADP saw the departures of Drs. Jevotovic-Todorovic, Oaklander, and Ramsay.  One new committee member was added as well a consumer representative.  This committee now has three vacancies. David S. Craig, PharmD joined the committee as of April 1st. Dr. Craig is the pharmacist lead at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida and a professor of pharmacy at the University of Florida College of Pharmacy. Jennifer Higgins, PhD has also joined the committee as a consumer representative. Dr. Higgins is the SAMHSA Grant Project Coordinator at the Center for Human Development in Springfield Massachusetts. Her term also began April 1st.

PDAC also so the addition of a consumer representative this month – Yanling Yu, MS, PhD joined the committee on April 1st. Dr. Yu is the President and Co-founder of Washington Advocates for Patient Safety. With Dr. Yu’s addition there are currently no vacancies on this committee.

Stay tuned for our mid-month roll call post – spotlight on the Peripheral and Central Nervous System Drugs Advisory Committee!

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

Interested in learning about ISS’ expert approach to Advisory Committee Meeting preparation? Click below in order to find out for yourself!

Roadmap to AdComm Success

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us